Floatz logo

DPA-714

Positron Emission Tomography

University of California, DavisSmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Positron Emission Tomography cohort.

Asset / SponsorPhaseRating
FCH
National Taiwan University Hospital
Phase 4BB
Psma-Hbed-Cc
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3B
GADOPENTETATE DIMEGLUMINE
National Taiwan University Hospital
Phase 4B
FLUDEOXYGLUCOSE
University of California, Davis
Early Phase 1C
DOTA-FAPI-04 GALLIUM GA-68
First Affiliated Hospital of Fujian Medical University
Early Phase 1C
CIMBI-36
University of Exeter
D
DASB
University of Exeter
D

Same molecule, other indications

DPA-714 is also rated in:

subjective cognitive declineDormant
CC
Indicative ·
47 / 100
View asset →
Parkinson diseaseDormant
CC
Indicative ·
46 / 100
View asset →
Epilepsy, Post-TraumaticDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →